



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Pacanalotamab

Cat. No.:	HY-P99798
CAS No.:	2251756-52-0
Target:	CD3
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Pacanalotamab (AMG 420; BI-836909) is a bispecific T-cell engager (BiTE) targeting to BCMA and CD3ε. BCMA refers to B cell maturation antigen, as Pacanalotamab redirecting T cells to BCMA expressing cells on the cell surface. Pacanalotamab conducts T-cell redirected lysis of human multiple myeloma (MM) cell lines ^[1] .									
IC₅₀ & Target	B cell maturation antigen, BCMA; CD3ε ^[1]									
In Vitro	<p>Pacanalotamab (1 pg/mL-100 ng/mL; 24 h) induces BCMA-dependent tumor cell lysis via T cells activation. And Pacanalotamab induces dose-dependent redirected lysis of human multiple myeloma cell lines with EC₉₀ values ranging from 16-810 pg/mL^[1].</p> <p>Pacanalotamab (100 ng/mL; 24 h) induces translocation of phosphatidylserine from the inner to the outer leaflet of the plasma membrane, leading to apoptosis in MM.1R cells^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>									
In Vivo	<p>Pacanalotamab (50 µg/kg/day; i.v. or s.c.; for 18 days) exhibits anti-tumor activity in mouse NCI-H929 xenograft model^[1]. Pacanalotamab (5 µg/kg/day; i.v. or s.c.) significant prolongs survival of mouse in mouse orthotopic L-363 xenograft model^[1].</p> <p>Pacanalotamab (135 µg/kg/day for i.v. or 405 µg/kg/day for s.c.; up to 28 days) is well tolerated, and it decreases plasma cells in the bone marrow in macaque in toxicity studies^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Cynomolgus monkey studies^[1]</td> </tr> <tr> <td>Dosage:</td> <td>(1) 0, 5, 15, 45 or 135 µg/kg/day, 20 mL/kg/day; (2) 135 or 405 µg/kg/day, 2 mL/kg/day</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection for (1) and subcutaneous injection for (2); for 7 days</td> </tr> <tr> <td>Result:</td> <td>Showed well tolerated among Cynomolgus monkeys. Clinical signs of toxicity were limited to vomiting and increased body temperature at 4-8 h.</td> </tr> </table>		Animal Model:	Cynomolgus monkey studies ^[1]	Dosage:	(1) 0, 5, 15, 45 or 135 µg/kg/day, 20 mL/kg/day; (2) 135 or 405 µg/kg/day, 2 mL/kg/day	Administration:	Intravenous injection for (1) and subcutaneous injection for (2); for 7 days	Result:	Showed well tolerated among Cynomolgus monkeys. Clinical signs of toxicity were limited to vomiting and increased body temperature at 4-8 h.
Animal Model:	Cynomolgus monkey studies ^[1]									
Dosage:	(1) 0, 5, 15, 45 or 135 µg/kg/day, 20 mL/kg/day; (2) 135 or 405 µg/kg/day, 2 mL/kg/day									
Administration:	Intravenous injection for (1) and subcutaneous injection for (2); for 7 days									
Result:	Showed well tolerated among Cynomolgus monkeys. Clinical signs of toxicity were limited to vomiting and increased body temperature at 4-8 h.									

REFERENCES

[1]. Hipp S, et al. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. *Leukemia*. 2017 Aug;31(8):1743-1751.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA